However, recent studies have revealed that increased DDX39B could promote the tumour metastasis of colorectal cancer and enhance chemotherapy resistance in BRCA1-proficient ovarian cancers (Xu Z. et al., 2020; He et al., 2021). Here, DDX39B is linked to ovarian cancer.